Perlindungan Korban terhadap Tindak Pidana Penganiayaan Berat

Skripsi ini membahas tentang Perlindungan Korban Terhadap Tindak Pidana Penganiayaan Berat, Perlindungan korban saat ini banyak mengalami persoalan, pelaksanaan penegakan hukum terhadap hak-hak korban masih banyak mengabaikan hak-hak korban dalam penanganan perkara pidana, Pemenuhan hak-hak korban dalam peraturan masih cenderung menimbulkan ketidak seimbangan kepentingan yaitu kepentingan tersangka atau terdakwa dan korban, hak-hak tersangka acapkali di tonjolkan sementara hak-hak korban masih banyak di abaikan. Penegakan hukum melalui sistem peradilan pidana saat ini perlu adanya perhatian khusus tentang bagaimana Hukumnya, melalui sistem peradilan pidana, yang sejatinya harus memerankan fungsinya sebagai sarana untuk menyelesaikan konflik, menegakkan kebenaran dan keadilan yang menjamin hak-hak korban. Dengan demikian, kedudukan korban dapat ditinjau melalui aspek viktimologi dimana viktimologi merupakan studi ilmu yang mempelajari tentang korban. Kebijakan melindungi masyarakat diarahkan kepada perlindungan dari berbagai gangguan terutama gangguan keamanan dan keselamatan jiwa, harta dan kehormatan. Sebagai perlindungan masyarakat, maka hak-hak korban di dijamin dan di atur dalam Undang-Undang No 31 Tahun 2014 Tentang perubahan atas Undang-Undang No. 13 Tahun 2006 Tentang Perlindungan Saksi dan Korban. namun mengenai aspek viktimologi belum terlalu ditekankan didalamnya termasuk di KUHP & KUHAP. Oleh karna itu, metode yang digunakan dalam penulisan skripsi ini adalah normatif yuridis, dengan dua pendekatan yaitu pendekatan konseptual dan pendekatan perundang-undangan. Sehingga undang-undang tentang perlindungan korban dalam perspektif viktimologi mampu mengakomodir eksistensi korban dalam mencari keadilan

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8–13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05–6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50–75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

GEDI waveform metrics in vegetation mapping—a case study from a heterogeneous tropical forest landscape

The distribution of different vegetation types is important information for landscape management, especially in the context of tackling global environmental change. Vegetation types can be mapped using satellite and airborne passive remote sensing. However, spectrally similar yet structurally different vegetation types, like different tree-dominated land covers, are often challenging to map using spectral information alone. We examined the potential of vertical vegetation structure acquired in the global ecosystem dynamics investigation (GEDI) mission that harnesses a space-borne waveform lidar sensor in vegetation mapping across a heterogeneous tropical landscape in Cambodia. We extracted 121 waveform metrics from Level-1B and Level-2A data products at 1062 locations across five key vegetation types. After reducing the relative height variables’ dimensionality through simple linear regressions, we developed a Random Forest classifier to predict vegetation classes based on 23 GEDI metrics. We then used this model to classify the vegetation types across more than 77 000 GEDI footprints in the study area. GEDI metrics alone were useful in identifying vegetation types with 81% accuracy. Cropland/grassland class had the highest prediction accuracy (user’s accuracy [UA] = 89%; producer’s accuracy [PA] = 91%), while dry deciduous forest had the lowest accuracy (UA = 73%; PA = 69%). By comparing the GEDI-only classification with an optical-radar map, we found that structural and topographic information from GEDI Level-1B and Level-2A can complement the spectral information in assessing natural habitats that neighbor other vegetation types in a heterogeneous landscape. The highest classification accuracy at the footprint scale was obtained from the combination of GEDI, Sentinel-1, and Sentinel-2 (88.3%). We also demonstrated how wall-to-wall vegetation mapping is possible by combining the three data sources. These findings expand the potential use of GEDI waveform lidar data in supporting the development of policy-relevant maps that depict the distribution of forests together with other vegetation types

Aplikasi Sistem Informasi Geografis untuk Kajian Perencanaan Rehabilitasi Hutan Mangrove di Kecamatan Punduh Pedada, Lampung

Mangrove forests are one of the coastal ecosystems that are under pressure due to antrophogenic activities, including land conversions to fishponds or aquaculture. On the other hand, the needs for seafood products from these aquaculture activities tend to increase annually. These situations become paradoxes that are often encountered within aquaculture management in Indonesia. Punduh Pidada Subdistrict is one of the areas in Pesawaran Regency, Lampung, that severely suffered from mangrove forest conversion into fishponds. The purposes of this study were to identify the trends in mangrove cover changes over 30 years and to design a mangrove rehabilitation plan in Punduh Pidada Subdistrict. This study used a time-series data of Landsat satellite imagery over 30 years, from 1989 to 2019. The results showed a significant decrease in the mangrove cover areas over 30 years at 83.34 Ha with an average mangrove cover losses at 30.5%. Three zones that are suitable for mangrove rehabilitation plan was then choosen based on the levels of mangrove loss areas, namely first priority rehabilitation plan covering zone 1 (1.7 Ha) and zone 2 (1.5 ha) and the second priority rehabilitation plan covering zone 3 (7.5 Ha).  With a planting distance of 1 x 2 meter, the total of seeds needed for the rehabilitation planning are 8,500 seeds for zone 1, 7,500 seeds for zone 2, and 27,500 seeds for zone 3

Survival analysis of patients with rheumatic MS after PBMV compared with MVS in a low-to-middle-income country

Introduction: Rheumatic mitral stenosis continues to be prevalent in developing countries, notably in endemic areas. Over the last few decades, percutaneous balloon mitral valvuloplasty (PBMV) has been established as a lower-cost alternative treatment for mitral stenosis (MS) in low-to-middle-income countries. PBMV has also been suggested to be an effective and safe alternative treatment modality. This study aims to analyse the survival of rheumatic MS patients treated with PBMV compared with those treated with mitral valve surgery (MVS). Methods: This study was a national, single-centre, longitudinal study using a survival analysis method in 329 consecutive patients suffering from rheumatic heart disease with severe MS who underwent PBMV compared with 142 consecutive patients with similar characteristics who underwent MVS between January 2011 and December 2016. Survival analysis and event-free duration were determined over a median follow-up of 24 months in the PBMV group and 27 months in the MVS group. Results: The results showed that of the 329 consecutive patients in the PBMV group, 61 patients (18.5) had an event (6 patients died and 55 patients were hospitalised), and of the 142 consecutive patients in the MVS group, 19 patients (13.4%) had an event (5 patients died, and 14 patients were hospitalised). The hazard ratio was 0.631 (95% confidence interval, 0.376–1.058; P = 0.081). Longer short-term survival was found in the MVS group but was not statistically significant. Event-free survival was significantly longer in the MVS group (P = 0.002), by 5 months. Conclusions: In this study, the efficacy and safety of PBMV was reconfirmed, as PBMV proved to be non-inferior to MVS in survival prognosis, but sustained event-free duration was significantly better in the MVS group than in the PBMV group